Cerebrolysin: A Porcine-Derived Neuropeptide Preparation

Research summary. Cerebrolysin is a parenteral neuropeptide preparation manufactured from porcine brain tissue through a controlled enzymatic breakdown process. Unlike single-molecule peptides, Cerebrolysin is a defined mixture of low-molecular-weight peptides and free amino acids derived from CNS tissue, designed to recapitulate the neurotrophic activity of endogenous brain growth factors. The product has been marketed in some jurisdictions in Europe, Asia, and Russia under the trade name Cerebrolysin (manufacturer EVER Pharma), but is not approved in the United States.

Composition and identifiers

• Source: Standardised lysate of purified porcine brain proteins
• Composition: ~25% low-molecular-weight peptides (typically <10 kDa); ~75% free amino acids
• CAS Number: 12656-61-0
• Synonyms: Cerebrolyzin, FPE-1070
• Formulation: Aqueous solution at 215 mg/mL

Because Cerebrolysin is a mixture rather than a single chemical entity, it does not have a single defined molecular structure. The therapeutic concept is that the small-peptide fraction includes biologically active oligopeptides that mimic, in functional terms, the neurotrophic activity of full-length proteins such as BDNF, GDNF, NGF, and CNTF, while the small molecular size confers improved blood–brain barrier permeability relative to the parent proteins.

Mechanism of action

Cerebrolysin is reported to recapitulate several effects associated with neurotrophic factor signalling:

• Neurotrophic mimicry. In vitro and in vivo studies have reported that the peptide fraction supports neuronal survival, dendritic outgrowth, and synaptic plasticity in cultured cortical and hippocampal neurons, with effects qualitatively similar to those produced by recombinant BDNF and NGF.
• Anti-apoptotic effects. Reduced caspase-3 activation and mitigation of mitochondrial dysfunction have been described in models of ischaemic and excitotoxic injury.
• Modulation of amyloid-β handling. Animal studies of Alzheimer's-relevant pathology have reported reductions in amyloid-β production and altered processing of amyloid precursor protein.
• Anti-inflammatory effects. Suppression of microglial activation and pro-inflammatory cytokine release has been reported in CNS injury models.

Preclinical and clinical research highlights

Cerebrolysin has accumulated an unusually large clinical literature relative to most peptide preparations because it has been an approved therapeutic in some jurisdictions for several decades.

Ischaemic stroke. Multiple randomised controlled trials and meta-analyses have evaluated Cerebrolysin administered after acute ischaemic stroke. Pooled analyses, including those drawing on the Cochrane systematic review framework, have reported small to moderate improvements in functional recovery scores, with the largest effects observed in patients with more severe baseline deficits and when treatment is initiated within 24–72 hours. Effect sizes vary across trials, and methodological heterogeneity remains a substantive caveat in the meta-analytic literature [1].

Alzheimer's disease and vascular dementia. Multi-month dosing courses have been examined in mild-to-moderate Alzheimer's disease and vascular dementia. Reported endpoints include measures of cognitive function (ADAS-cog) and global clinical impression, with several trials reporting modest cognitive benefit during and after treatment courses.

Traumatic brain injury. Trials in moderate-to-severe TBI, particularly the CAPTAIN-1 and CAPTAIN-2 studies, have reported improvements on multidimensional outcome measures.

Cerebral palsy and developmental neurology. Paediatric studies have examined Cerebrolysin as adjunctive therapy alongside structured rehabilitation, with reported improvements in motor and cognitive metrics.

Pain models. Rodent models of chronic migraine and neuropathic pain have reported reductions in TNF-α and IL-1β alongside attenuation of pain behaviours following administration.

Regulatory status

Cerebrolysin is licensed as a therapeutic in numerous jurisdictions including Russia, China, parts of Europe, and several Asian countries, but it is not approved by the U.S. FDA. The U.S. FDA has granted orphan drug designation for selected rare neurological indications, but no marketing authorisation. The dossier of evidence is unusually large for a research peptide product but has not satisfied U.S. regulatory standards, partly owing to questions about the consistency of the active fraction across manufacturing lots and the heterogeneity of trial outcomes.

Limitations of the evidence base

Cerebrolysin presents a distinctive interpretive challenge because it is a complex mixture rather than a single chemical entity. This raises issues including:

• Difficulty in defining the active pharmaceutical ingredient at the molecular level
• Lot-to-lot consistency of the peptide fraction
• Difficulty replicating the formulation outside the manufacturer's process
• Heterogeneity of clinical-trial designs and outcome measures across decades of investigation

Current research status

Cerebrolysin remains an approved therapeutic in some jurisdictions and an investigational preparation in others. Within research contexts it serves as a benchmark for studies of neurotrophic-factor mimetics and as a comparator in CNS injury and neurodegeneration models.

Key takeaways for researchers

• Cerebrolysin is a defined mixture of small peptides and amino acids derived from porcine brain tissue.
• Its mechanism is best understood as functional mimicry of multiple neurotrophic factors rather than action through a single receptor.
• It has been studied across stroke, dementia, TBI, cerebral palsy, and pain, with the largest body of evidence in ischaemic stroke.
• It is approved in several jurisdictions but not in the United States.

References

1. Ziganshina LE, Abakumova T, Hoyle CHV. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 2020;7:CD007026.

---

This article is provided for educational and research purposes only. Cerebrolysin is a complex peptide preparation. It is not approved by the U.S. Food and Drug Administration and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition outside of jurisdictions where it is legally licensed and prescribed by a qualified clinician. All research work involving this product should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.